Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(NY: AHR )

26.08 -0.23 (-0.87%)
Official Closing Price Updated: 4:10 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about AHR

Top 4 Real Estate Stocks You May Want To Dump In September
Via Benzinga
Nike To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
Steelcase Reports Weak Sales, Joins American Healthcare REIT And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Top 2 Real Estate Stocks That May Collapse This Month
Via Benzinga
AHR Stock Earnings: American Healthcares Reported Results for Q2 2024
American Healthcares just reported results for the second quarter of 2024. 
Via InvestorPlace
Unveiling 11 Analyst Insights On American Healthcares
Via Benzinga
Deep Dive Into American Healthcares Stock: Analyst Perspectives (10 Ratings)
Via Benzinga
Mortgage Rates Fall To 15-Month Lows, Boost Homebuyer Demand As Federal Reserve Hints At Rate Cuts
Bond yields drop on expectations of Fed rate cut, leading to lowest mortgage rates in over a year and surge in mortgage applications for both new and refinancing loans. 
Via Benzinga
Topics Economy
Exposures Interest Rates
AHR Stock Earnings: American Healthcares Misses EPS, Beats Revenue for Q1 2024
AHR stock results show that American Healthcares missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
The 3 Best Stocks to Buy If You Only Have $100 to Invest: March Edition
These are the best stocks to buy with $100, proving you don't need a lot of money to make a lot of money on Wall Street. 
Via InvestorPlace
Newly Listed American Healthcare REIT: Stock Trades At Discount, But Analysts Favor Its Risk-Reward Balance
American Healthcare REIT (AHR) post-IPO success, with Truist's Buy rating projecting 32% return, and RBC's Outperform rating highlighting strong earnings growth. JMP sees potential multiple expansion,... 
Via Benzinga
Gilead-Backed Kyverna Overshoots Raised IPO Expectations
Kyverna Therapeutics raised almost $320 million in its initial public offering, which was priced above the marketed range. Backed by Gilead Sciences, the company's offering was the second largest for a... 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.